Table 3.
Multivariate Analysis for Nuclear p-AKT Overexpression in DLBCL, GCB-DLBCL, and ABC-DLBCL
| Variable | Overall survival |
Progression-free survival |
||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| DLBCL | ||||
| IPI >2 | 2.47 (1.76–3.47) | <0.001 | 2.27 (1.65–3.14) | <0.001 |
| Female sex | 1.00 (0.71–1.40) | 1.00 | 0.98 (0.71–1.35) | 0.89 |
| Tumor size >5 cm | 1.33 (0.96–1.86) | 0.09 | 1.27 (0.93–1.75) | 0.13 |
| B-symptoms | 1.37 (0.97–1.94) | 0.075 | 1.37 (0.99–1.91) | 0.061 |
| Nuclear p-AKThigh | 1.30 (0.89–1.90) | 0.18 | 1.40 (0.98–2.00) | 0.068 |
| GCB-DLBCL | ||||
| IPI >2 | 3.51 (2.08–5.92) | <0.001 | 3.40 (2.09–5.55) | <0.001 |
| Female sex | 0.96 (0.57–1.61) | 0.87 | 1.04 (0.64–1.685) | 0.88 |
| Tumor size >5 cm | 1.50 (0.90–2.50) | 0.12 | 1.45 (0.90–2.34) | 0.13 |
| B-symptoms | 1.38 (0.82–2.33) | 0.23 | 1.27 (0.77–2.10) | 0.35 |
| Nuclear p-AKThigh | 1.15 (0.61–2.17) | 0.67 | 1.39 (0.78–2.48) | 0.27 |
| ABC-DLBCL | ||||
| IPI >2 | 2.36 (1.52–3.66) | <0.001 | 2.337 (1.50–3.62) | <0.001 |
| Female sex | 1.01 (0.64–1.59) | 0.96 | 1.00 (0.64–1.58) | 1.00 |
| Tumor size >5 cm | 1.40 (0.90–2.17) | 0.14 | 1.41 (0.90–2.20) | 0.13 |
| B-symptoms | 1.24 (0.78–1.96) | 0.37 | 1.25 (0.79–2.00) | 0.34 |
| Nuclear p-AKThigh | 1.43 (0.88–2.30) | 0.15 | 1.45 (0.90–2.34) | 0.13 |
ABC, activated B-cell–like; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell–like; HR, hazard ratio; IPI, International Prognostic Index; p-AKThigh, high levels (≥70%) of phospho-AKT expression.